{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T23:12:54Z","timestamp":1792537974256,"version":"4.5.0"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,12]],"date-time":"2023-02-12T00:00:00Z","timestamp":1676160000000},"content-version":"am","delay-in-days":348,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.jconrel.2022.01.022","type":"journal-article","created":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T20:42:29Z","timestamp":1642711349000},"page":"518-527","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["A PBPK model recapitulates early kinetics of anti-PEG antibody-mediated clearance of PEG-liposomes"],"prefix":"10.1016","volume":"343","author":[{"given":"Anne M.","family":"Talkington","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan D.","family":"McSweeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Wessler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marielle K.","family":"Rath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zibo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan E.","family":"Frank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Gregory","family":"Forest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanguang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel K.","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2022.01.022_bb0005","doi-asserted-by":"crossref","first-page":"6288","DOI":"10.1002\/anie.200902672","article-title":"Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives","volume":"49","author":"Knop","year":"2010","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.jconrel.2022.01.022_bb0010","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1177\/0192623315591171","article-title":"PEGylated biopharmaceuticals: current experience and considerations for nonclinical development","volume":"43","author":"Ivens","year":"2015","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.jconrel.2022.01.022_bb0015","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1517\/14728214.2015.1113254","article-title":"What is the future of PEGylated therapies?","volume":"20","author":"Swierczewska","year":"2015","journal-title":"Exp. Opin. Emerg. Drugs"},{"key":"10.1016\/j.jconrel.2022.01.022_bb0020","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.intimp.2012.12.012","article-title":"The impact of PEGylation on protein immunogenicity","volume":"15","author":"Gefen","year":"2013","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.jconrel.2022.01.022_bb0025","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2165\/00063030-200822050-00004","article-title":"The impact of PEGylation on biological therapies","volume":"22","author":"Veronese","year":"2008","journal-title":"BioDrugs"},{"key":"10.1016\/j.jconrel.2022.01.022_bb0030","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S1359-6446(05)03575-0","article-title":"PEGylation, successful approach to drug delivery","volume":"10","author":"Veronese","year":"2005","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jconrel.2022.01.022_bb0035","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/biot.200900218","article-title":"PEGylation of therapeutic proteins","volume":"5","author":"Jev\u0161evar","year":"2010","journal-title":"Biotechnol. J."},{"key":"10.1016\/j.jconrel.2022.01.022_bb0040","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/wnan.1339","article-title":"Anti-PEG immunity: emergence, characteristics, and unaddressed questions, Wiley interdisciplinary reviews","volume":"7","author":"Yang","year":"2015","journal-title":"Nanomed. Nanobiotechnol."},{"key":"10.1016\/j.jconrel.2022.01.022_bb0045","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.procbio.2016.09.029","article-title":"Effect of protein immunogenicity and PEG size and branching on the anti-PEG immune response to PEGylated proteins","volume":"52","author":"Wan","year":"2017","journal-title":"Process Biochem."},{"key":"10.1016\/j.jconrel.2022.01.022_bb0050","doi-asserted-by":"crossref","first-page":"13873","DOI":"10.1002\/anie.201808615","article-title":"Revealing the immunogenic risk of polymers","volume":"57","author":"Li","year":"2018","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.jconrel.2022.01.022_bb0055","doi-asserted-by":"crossref","first-page":"11804","DOI":"10.1021\/acs.analchem.6b03437","article-title":"Analysis of pre-existing IgG and IgM antibodies against polyethylene glycol (PEG) in the general population","volume":"88","author":"Yang","year":"2016","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jconrel.2022.01.022_bb0060","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/cncr.22739","article-title":"Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients","volume":"110","author":"Armstrong","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.jconrel.2022.01.022_bb0065","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar4500","article-title":"Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients","volume":"16","author":"Hershfield","year":"2014","journal-title":"Arthritis Res. Therapy"},{"key":"10.1016\/j.jconrel.2022.01.022_bb0070","doi-asserted-by":"crossref","first-page":"R60","DOI":"10.1186\/ar4497","article-title":"Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout","volume":"16","author":"Lipsky","year":"2014","journal-title":"Arthritis Res. Therapy"},{"key":"10.1016\/j.jconrel.2022.01.022_bb0075","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/art.22403","article-title":"Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout","volume":"56","author":"Sundy","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jconrel.2022.01.022_bb0080","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0140-6736(13)61841-3","article-title":"Single-dose, subcutaneous recombinant phenylalanine ammonia lyase conjugated with polyethylene glycol in adult patients with phenylketonuria: an open-label, multicentre, phase 1 dose-escalation trial","volume":"384","author":"Longo","year":"2014","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.jconrel.2022.01.022_bb0085","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jconrel.2013.07.026","article-title":"The accelerated blood clearance (ABC) phenomenon: clinical challenge and approaches to manage","volume":"172","author":"Abu Lila","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.01.022_bb0090","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.ultrasmedbio.2018.02.006","article-title":"Accelerated clearance of ultrasound contrast agents containing polyethylene glycol is associated with the generation of anti-polyethylene glycol antibodies","volume":"44","author":"Fix","year":"2018","journal-title":"Ultrasound Med. Biol."},{"key":"10.1016\/j.jconrel.2022.01.022_bb0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/pharmaceutics3010001","article-title":"Anti-PEG IgM response against PEGylated liposomes in mice and rats","volume":"3","author":"Ichihara","year":"2010","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2022.01.022_bb0100","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jconrel.2005.04.003","article-title":"Accelerated blood clearance of PEGylated liposomes following preceding liposome injection: effects of lipid dose and PEG surface-density and chain length of the first-dose liposomes","volume":"105","author":"Ishida","year":"2005","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.01.022_bb0105","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jconrel.2007.05.015","article-title":"PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner","volume":"122","author":"Ishida","year":"2007","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.01.022_bb0110","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1080\/14686996.2019.1627174","article-title":"PEGylated liposomes: immunological responses","volume":"20","author":"Mohamed","year":"2019","journal-title":"Sci. Technol. Adv. Mater."},{"key":"10.1016\/j.jconrel.2022.01.022_bb0115","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics12010015","article-title":"Both IgM and IgG antibodies against polyethylene glycol can Alter the biological activity of Methoxy polyethylene glycol-Epoetin Beta in mice","volume":"12","author":"Chang","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2022.01.022_bb0120","doi-asserted-by":"crossref","first-page":"4981","DOI":"10.4049\/jimmunol.1202017","article-title":"Fc\u03b3RIIb on liver sinusoidal endothelium clears small immune complexes","volume":"189","author":"Ganesan","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2022.01.022_bb0125","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.addr.2020.07.024","article-title":"Anti-PEG antibodies: properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals","volume":"154\u2013155","author":"Kozma","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2022.01.022_bb0130","doi-asserted-by":"crossref","first-page":"9315","DOI":"10.1021\/acsnano.9b03942","article-title":"Pseudo-anaphylaxis to polyethylene glycol (PEG)-coated liposomes: roles of anti-PEG IgM and complement activation in a porcine model of human infusion reactions","volume":"13","author":"Kozma","year":"2019","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2022.01.022_bb0135","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s13075-017-1396-8","article-title":"Frequency, distribution and immunologic nature of infusion reactions in subjects receiving pegloticase for chronic refractory gout","volume":"19","author":"Calabrese","year":"2017","journal-title":"Arthritis Res. Therapy"},{"key":"10.1016\/j.jconrel.2022.01.022_bb0140","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1001\/jama.2011.1169","article-title":"Efficacy and tolerability of Pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials","volume":"306","author":"Sundy","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.jconrel.2022.01.022_bb0145","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1016\/j.jaci.2016.04.058","article-title":"Pre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamer","volume":"138","author":"Povsic","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.jconrel.2022.01.022_bb0150","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/jcph.1824","article-title":"PEG that reaction: a case series of allergy to polyethylene glycol","volume":"61","author":"Cox","year":"2021","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.jconrel.2022.01.022_bb0155","doi-asserted-by":"crossref","first-page":"26","DOI":"10.5414\/ALX02215E","article-title":"Severe allergic reactions to the COVID-19 vaccine - statement and practical consequences","volume":"5","author":"Kleine-Tebbe","year":"2021","journal-title":"Allergol Select"},{"key":"10.1016\/j.jconrel.2022.01.022_bb0160","doi-asserted-by":"crossref","first-page":"72","DOI":"10.5414\/ALX02225E","article-title":"Practical recommendations for the allergological risk assessment of the COVID-19 vaccination - a harmonized statement of allergy centers in Germany","volume":"5","author":"Worm","year":"2021","journal-title":"Allergol Select"},{"key":"10.1016\/j.jconrel.2022.01.022_bb0165","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics11030110","article-title":"Pharmacokinetics and pharmacodynamics modeling and simulation systems to support the development and regulation of liposomal drugs","volume":"11","author":"He","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2022.01.022_bb0170","doi-asserted-by":"crossref","DOI":"10.1088\/1742-6596\/429\/1\/012019","article-title":"Using a PBPK model to study the influence of different characteristics of nanoparticles on their biodistribution","volume":"429","author":"Li","year":"2013","journal-title":"J. Phys. Conf. Ser."},{"key":"10.1016\/j.jconrel.2022.01.022_bb0175","doi-asserted-by":"crossref","first-page":"6303","DOI":"10.1021\/nn1018818","article-title":"Physiologically based pharmacokinetic modeling of nanoparticles","volume":"4","author":"Li","year":"2010","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2022.01.022_bb0180","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1208\/s12248-016-0010-3","article-title":"Physiologically based pharmacokinetic (PBPK) modeling of pharmaceutical nanoparticles","volume":"19","author":"Li","year":"2017","journal-title":"AAPS J."},{"key":"10.1016\/j.jconrel.2022.01.022_bb0185","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/bcp.12878","article-title":"Development of a physiologically based pharmacokinetic model of actinomycin D in children with cancer","volume":"81","author":"Walsh","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.jconrel.2022.01.022_bb0190","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/00001813-200207000-00010","article-title":"Non-linear pharmacokinetics of irinotecan in mice","volume":"13","author":"Rouits","year":"2002","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.jconrel.2022.01.022_bb0195","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/psp4.12101","article-title":"Predictive performance of physiologically based pharmacokinetic and population pharmacokinetic modeling of Renally cleared drugs in children","volume":"5","author":"Zhou","year":"2016","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.jconrel.2022.01.022_bb0200","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/bcp.12702","article-title":"Optimizing pharmacokinetic bridging studies in paediatric oncology using physiologically-based pharmacokinetic modelling: application to docetaxel","volume":"80","author":"Thai","year":"2015","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.jconrel.2022.01.022_bb0205","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3109\/17435390.2014.940404","article-title":"Using physiologically based pharmacokinetic (PBPK) modeling for dietary risk assessment of titanium dioxide (TiO2) nanoparticles","volume":"9","author":"Bachler","year":"2015","journal-title":"Nanotoxicology"},{"key":"10.1016\/j.jconrel.2022.01.022_bb0210","first-page":"3365","article-title":"A physiologically based pharmacokinetic model for ionic silver and silver nanoparticles","volume":"8","author":"Bachler","year":"2013","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2022.01.022_bb0215","doi-asserted-by":"crossref","first-page":"7311","DOI":"10.1113\/JP274819","article-title":"Interstitial IgG antibody pharmacokinetics assessed by combined in vivo- and physiologically-based pharmacokinetic modelling approaches","volume":"595","author":"Eigenmann","year":"2017","journal-title":"J. Physiol."},{"key":"10.1016\/j.jconrel.2022.01.022_bb0220","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s10928-007-9065-1","article-title":"Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice","volume":"34","author":"Garg","year":"2007","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.jconrel.2022.01.022_bb0225","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jconrel.2019.08.017","article-title":"Overcoming anti-PEG antibody mediated accelerated blood clearance of PEGylated liposomes by pre-infusion with high molecular weight free PEG","volume":"311-312","author":"McSweeney","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.01.022_bb0230","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jconrel.2018.06.002","article-title":"A minimal physiologically based pharmacokinetic model that predicts anti-PEG IgG-mediated clearance of PEGylated drugs in human and mouse","volume":"284","author":"McSweeney","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.01.022_bb0235","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.jconrel.2020.10.011","article-title":"Pre-treatment with high molecular weight free PEG effectively suppresses anti-PEG antibody induction by PEG-liposomes in mice","volume":"329","author":"McSweeney","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.01.022_bb0240","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/nprot.2010.13","article-title":"Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine","volume":"5","author":"Vosjan","year":"2010","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.jconrel.2022.01.022_bb0245","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.nucmedbio.2014.11.005","article-title":"The impact of weakly bound 89Zr on preclinical studies: non-specific accumulation in solid tumors and aspergillus infection","volume":"42","author":"Severin","year":"2015","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.jconrel.2022.01.022_bb0250","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1007\/s00259-016-3499-x","article-title":"Comparison of the octadentate bifunctional chelator DFO*-pPhe-NCS and the clinically used hexadentate bifunctional chelator DFO-pPhe-NCS for (89)Zr-immuno-PET","volume":"44","author":"Vugts","year":"2017","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.jconrel.2022.01.022_bb0255","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1023\/A:1018943613122","article-title":"Physiological parameters in laboratory animals and humans","volume":"10","author":"Davies","year":"1993","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2022.01.022_bb0260","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1177\/074823379701300401","article-title":"Physiological parameter values for physiologically based pharmacokinetic models","volume":"13","author":"Brown","year":"1997","journal-title":"Toxicol. Ind. Health"},{"key":"10.1016\/j.jconrel.2022.01.022_bb0265","series-title":"Proceedings of the Society for Experimental Biology and Medicine","first-page":"16","article-title":"Plasma and blood volumes of mouse organs, as determined with radioactive iodoproteins","volume":"75","author":"Kaliss","year":"1950"},{"key":"10.1016\/j.jconrel.2022.01.022_bb0270","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/psp.2013.41","article-title":"Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development","volume":"2","author":"Jones","year":"2013","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.jconrel.2022.01.022_bb0275","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s11538-021-00950-z","article-title":"Experimental data and PBPK modeling quantify antibody interference in PEGylated drug carrier delivery","volume":"83","author":"Talkington","year":"2021","journal-title":"Bull. Math. Biol."},{"key":"10.1016\/j.jconrel.2022.01.022_bb0280","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jtbi.2008.04.011","article-title":"A methodology for performing global uncertainty and sensitivity analysis in systems biology","volume":"254","author":"Marino","year":"2008","journal-title":"J. Theor. Biol."},{"key":"10.1016\/j.jconrel.2022.01.022_bb0285","doi-asserted-by":"crossref","first-page":"323","DOI":"10.13182\/NSE89-A23645","article-title":"Expert opinion in risk analysis: the NUREG-1150 methodology","volume":"102","author":"Hora","year":"1989","journal-title":"Nucl. Sci. Eng."},{"key":"10.1016\/j.jconrel.2022.01.022_bb0290","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.jconrel.2021.08.051","article-title":"High MW polyethylene glycol prolongs circulation of pegloticase in mice with anti-PEG antibodies","volume":"338","author":"Talkington","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.01.022_bb0295","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s10928-011-9232-2","article-title":"Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human","volume":"39","author":"Shah","year":"2012","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.jconrel.2022.01.022_bb0300","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1208\/s12248-013-9517-z","article-title":"A mathematical model of the effect of immunogenicity on therapeutic protein pharmacokinetics","volume":"15","author":"Chen","year":"2013","journal-title":"AAPS J."},{"key":"10.1016\/j.jconrel.2022.01.022_bb0305","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s10928-014-9367-z","article-title":"Review on modeling anti-antibody responses to monoclonal antibodies","volume":"41","author":"G\u00f3mez-Mantilla","year":"2014","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.jconrel.2022.01.022_bb0310","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s00280-016-3018-6","article-title":"Sorafenib metabolism, transport, and enterohepatic recycling: physiologically based modeling and simulation in mice","volume":"77","author":"Edginton","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jconrel.2022.01.022_bb0315","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/2193-9616-1-6","article-title":"Using Bayesian-PBPK modeling for assessment of inter-individual variability and subgroup stratification","volume":"1","author":"Krauss","year":"2013","journal-title":"In Silico Pharmacol."},{"key":"10.1016\/j.jconrel.2022.01.022_bb0320","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/bcp.12234","article-title":"Combining the \u2018bottom up\u2019 and \u2018top down\u2019 approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical data","volume":"79","author":"Tsamandouras","year":"2015","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.jconrel.2022.01.022_bb0325","first-page":"407","article-title":"Which bifunctional chelator for immunoPET with Cu-64?","volume":"52","author":"Cooper","year":"2011","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2022.01.022_bb0330","first-page":"1385","article-title":"Synthesis, biodistribution and metabolic analysis of Cu-64 labeled PSMA-targeted ligand","volume":"57","author":"Cui","year":"2016","journal-title":"J. Nucl. Med."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365922000360?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365922000360?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T16:27:29Z","timestamp":1759163249000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365922000360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":66,"alternative-id":["S0168365922000360"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2022.01.022","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A PBPK model recapitulates early kinetics of anti-PEG antibody-mediated clearance of PEG-liposomes","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2022.01.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}